Oct 17, 2024, 16:04
Estela Rodriguez: Novocure’s Optune Lua TTF (device) plus docetaxel or Immunotherapy for 2L NSCLC
Estela Rodriguez shared a post on X:
“Its only Tuesday and we have another FDA Oncology approval for Novocure’s Optune Lua TTF (device) plus docetaxel or Immunotherapy for 2L NSCLC:
- Ph3 LUNAR study
- OS in ImmunoTx and TTF: 19m vs 10.8m.
- Pt compliance with a vest for 18 hrs/day.”
More posts featuring Estela Rodriguez.
Estela (Estelamari) Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32
Aug 1, 2025, 17:56